Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-BCAT in Advanced or Metastatic Hepatocellular Carcinoma
NCT06600321Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 1, open-label trial of ALN-BCAT in hepatocellular carcinoma (HCC) (4 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Frequency of Adverse Events, Severity of Adverse Events and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
ALN-BCAT
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06600321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600321.